Shutenko Z - Search Results

1

Pterin interactions with distinct reductase activities of NO synthase.

Pantke MM, Reif A, Valtschanoff JG, Shutenko Z, Frey A, Weinberg RJ, Pfleiderer W, Schmidt HH. Pantke MM, et al. Among authors: shutenko z. Biochem J. 2001 May 15;356(Pt 1):43-51. doi: 10.1042/0264-6021:3560043. Biochem J. 2001. PMID: 11336634 Free PMC article.

2

Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide.

Kotsonis P, Fröhlich LG, Shutenko ZV, Horejsi R, Pfleiderer W, Schmidt HH. Kotsonis P, et al. Among authors: shutenko zv. Biochem J. 2000 Mar 15;346 Pt 3(Pt 3):767-76. Biochem J. 2000. PMID: 10698705 Free PMC article.

3

Superoxide dismutase and catalase are required to detect (.-)NO from both coupled and uncoupled neuronal no synthase.

Reif A, Shutenko ZV, Feelisch M, Schmidt HH. Reif A, et al. Among authors: shutenko zv. Free Radic Biol Med. 2004 Oct 1;37(7):988-97. doi: 10.1016/j.freeradbiomed.2004.07.005. Free Radic Biol Med. 2004. PMID: 15336315

4

Influence of the antioxidant quercetin in vivo on the level of nitric oxide determined by electron paramagnetic resonance in rat brain during global ischemia and reperfusion.

Shutenko Z, Henry Y, Pinard E, Seylaz J, Potier P, Berthet F, Girard P, Sercombe R. Shutenko Z, et al. Biochem Pharmacol. 1999 Jan 15;57(2):199-208. doi: 10.1016/s0006-2952(98)00296-2. Biochem Pharmacol. 1999. PMID: 9890569

5

3-(2,2,2-Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties.

Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuķe RJ, Molodchina TN, Kalviņs IJ, Lukevics E. Simkhovich BZ, et al. Among authors: shutenko zv. Biochem Pharmacol. 1988 Jan 15;37(2):195-202. doi: 10.1016/0006-2952(88)90717-4. Biochem Pharmacol. 1988. PMID: 3342076

6

[Regulation of carnitine-dependent metabolism of fatty acids in the rat myocardium using 3-(2,2,2-trimethylhydrazinium) propionate].

Shutenko ZhV, Simkhovich BZ, Meĭrena DV, Kalvin'sh IIa, Lukevits EIa. Shutenko ZhV, et al. Vopr Med Khim. 1989 Mar-Apr;35(2):59-64. Vopr Med Khim. 1989. PMID: 2741413 Russian.

7

[Effect of DL-carnitine and gamma-butyrobetaine hydroxylase inhibitor 3-(2,2,2-trimethylhydrazinium) propionate on isoproterenol-induced changes in the metabolism of the rat myocardium].

Simkhovich BZ, Meĭrena DV, Shutenko ZhV, Khagi KhB, Briede IaL. Simkhovich BZ, et al. Among authors: shutenko zhv. Vopr Med Khim. 1988 Sep-Oct;34(5):30-4. Vopr Med Khim. 1988. PMID: 3218133 Russian.

8

[Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level].

Simkhovich BZ, Vitolinia RO, Stivrinia MI, Shutenko ZhV, Meĭrena DV. Simkhovich BZ, et al. Among authors: shutenko zhv. Kardiologiia. 1987 Jul;27(7):85-8. Kardiologiia. 1987. PMID: 3656926 Russian.

9

[The effect of mildronate on carnitine-dependent and carnitine-independent ketogenesis in rats].

Simkhovich BZ, Meĭrena DV, Khagi KhB, Shutenko ZhV, Molodchina TN, Kalvin'sh IIa, Lukevits EIa. Simkhovich BZ, et al. Among authors: shutenko zhv. Farmakol Toksikol. 1991 Jul-Aug;54(4):41-2. Farmakol Toksikol. 1991. PMID: 1786824 Russian.

10

[Potentiation of the antiketogenic effect of exogenous glucose with the help of the new beta-oxidation inhibitor mildronate--3-(2,2,2-trimethylhydrazine)propionate].

Shutenko ZhV, Meĭrena DV, Kalvin'sh IIa, Lukevits EIa. Shutenko ZhV, et al. Vopr Med Khim. 1991 Mar-Apr;37(2):59-60. Vopr Med Khim. 1991. PMID: 1897198 Russian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters